High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022–23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)
The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) conducted a study in Cambodia from January 2022 to June 2023, revealing a high prevalence of ceftriaxone-resistant, MDR, and XDR N. gonorrhoeae. The study found that resistance to ceftriaxone, cefixime, azithromycin, and ciprofloxacin was 15.4%, 43.1%, 14.4%, and 97.1%, respectively. 6.2% of isolates were resistant to all four antimicrobials, indicating the need for expanded surveillance, revision of treatment, mandatory test of cure, enhanced sexual contact notification, and the development of novel antimicrobials for gonorrhoea treatment.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!